IBI 306

Drug Profile

IBI 306

Alternative Names: IBI-306

Latest Information Update: 03 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Innovent Biologics
  • Class Antihyperlipidaemics; Cardiovascular therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Hyperlipidaemia

Most Recent Events

  • 08 Dec 2017 Innovent Biologics (Suzhou) plans a phase I trial for Hypercholesterolemia (In volunteers) in December 2017 (NCT03366688)
  • 03 Dec 2015 Early research in Hyperlipidaemia in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top